Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

HPV-010 Subject Treatment Allocation - Cervarix, September 26, 2007

To: Mr. Matthew Whitman
File: STN 125259/0 CERVARIX
RE: HPV-010 Subject Treatment Allocation
Date: September 26, 2007

Please refer to study HPV-010. Within the meta-analysis for potentially autoimmune events, subject PID #1658, who received either Gardasil or Cervarix, developed possible MS at 33 days after dose 2 of blinded study material. We acknowledge that the study is ongoing, but please provide the treatment allocation for this subject by the unblinded statistician as soon as possible.

Page Last Updated: 04/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English